Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at DDW 2022

Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at DDW 2022.

Related Keywords

Roseville ,California ,United States ,San Diego ,Switzerland ,American ,Sahil Khanna ,Glenn Tillotson ,Lisa Ellen ,Paul Feuerstadt ,Ken Blount ,Centers For Disease ,Us Centers For Disease ,American Society For Gastrointestinal Endoscopy ,Brand Communications ,Linkedin ,Society For Surgery Of The Alimentary Tract ,Ferring Pharmaceuticals ,Drug Administration ,Ferring Company ,Yale University School Of Medicine ,Rebiotix Inc ,American Gastroenterological Association ,Digestive Disease Week ,Infection Treated ,Mayo Clinic ,Treatment Success ,Reducing Recurrent Clostridioides ,Patients With Underlying ,Assistant Clinical Professor ,Yale University School ,New Haven ,Disease Control ,Fast Track ,Breakthrough Therapy ,American Association ,Liver Diseases ,American Society ,Gastrointestinal Endoscopy ,Alimentary Tract ,Biggest Threats ,Dis Clin North ,Manag Care Spec ,Clin Microbiol ,Rev Dis ,Bacteria ,Disease ,Infection ,Medical Specialties ,Merger And Acquisition ,Microbiology ,Spain ,Pharmaceuticals ,Antibiotic Resistant Bacteria ,C Diff ,Clostridiaceae ,Clostridioides Difficile ,Clostridium ,Clostridium Difficile ,Diarrhea ,Gram Positive Bacteria ,